epcoritamab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
epcoritamab

GtoPdb Ligand ID: 11442

Synonyms: epcoritamab-bysp | Epkinly® | GEN-3013 | GEN3013 | Tepkinly®

epcoritamab is an approved drug (FDA & EMA (2023))

Compound class: Antibody

Comment: Epcoritamab (GEN3013) is a novel CD3ε/CD20 bispecific IgG1 antibody that redirects CD3⁺ cytotoxic T cells to selectively destroy CD20+ve malignant B cells [1,3]. Its Fc domain has been mutated to prevent FcγR and complement binding.

References
1. Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ et al.. (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine, 52: 102625. [PMID:31981978]
2. Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R et al.. (2026) Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet, 407 (10524): 161-173. [PMID:41371238]
3. Romero D. (2023) Epcoritamab is active in large B cell lymphomas. Nat Rev Clin Oncol, 20 (3): 138. [PMID:36646813]
4. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W et al.. (2023) Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol, 41 (12): 2238-2247. [PMID:36548927]
5. van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S et al.. (2021) Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J, 11 (2): 38. [PMID:33602901]

References

1. Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ et al.. (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
EBioMedicine, 52: 102625. [PMID:31981978]

2. Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R et al.. (2026)
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Lancet, 407 (10524): 161-173. [PMID:41371238]

3. Romero D. (2023)
Epcoritamab is active in large B cell lymphomas.
Nat Rev Clin Oncol, 20 (3): 138. [PMID:36646813]

4. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W et al.. (2023)
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
J Clin Oncol, 41 (12): 2238-2247. [PMID:36548927]

5. van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S et al.. (2021)
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
Blood Cancer J, 11 (2): 38. [PMID:33602901]